To explore the role of socioeconomic factors in the initiation of SGLT2 inhibitor therapy among patients with chronic heart failure, addressing health disparities in cardiovascular care.
Approach:
Data Source: Utilized the German Analysis Database for Evaluation and Health Services Research (DADB) and the INKAR database for demographic and socioeconomic indicators.
Study Population: Included individuals with full insurance coverage diagnosed with left ventricular failure or unspecified heart failure in 2023, excluding those with contraindications for SGLT2i therapy.
Medication and Outcome: Main outcome was the initiation of SGLT2i therapy (dapagliflozin and empagliflozin) in 2023.
Covariate Assessment: Assessed various covariates including age, gender, nationality, socioeconomic status, and health program enrollment.
Statistical Methods: Conducted multilevel logistic regression analysis to identify factors associated with SGLT2i initiation.
Key Findings:
Socioeconomic factors significantly influence the initiation of SGLT2i therapy in heart failure patients.
Disparities in prescription rates may exist based on individual and area-level socioeconomic status.
Interpretation:
The study highlights the need to understand how socioeconomic factors affect access to SGLT2i therapy in heart failure management.
Limitations:
The study is limited to claims data, which may not capture all relevant clinical information.
Exclusion of patients with contraindications may limit generalizability.
Conclusion:
Understanding the impact of socioeconomic status on SGLT2i initiation can inform strategies to improve access and adherence in heart failure care.
Moderate coffee consumption generally appeared safe for most adults, but randomized evidence suggested divergent effects on atrial fibrillation and premature ventricular contractions.
Three of 23 patients experienced heart failure deterioration following medication withdrawal, while adverse drug events occurred only among patients who continued therapy.
